Trial Profile

Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Acronyms FIGHT

Most Recent Events

01 Oct 2023 Planned primary completion date changed from 15 Sep 2022 to 15 Sep 2026.
02 Apr 2022 Status changed from not yet recruiting to recruiting.
23 Aug 2021 Planned End Date changed from 1 Jul 2027 to 15 Sep 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com